• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23475 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2008     NIHR Health Technology Assessment programme 'Cut down to quit' with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis
1999     NIHR Health Technology Assessment programme 'Early warning systems' for identifying new healthcare technologies
2001     Danish Institute for Health Services Research (DSI) 'Health projekc Ebeltoft'. General practitioners valuation of organisational aspects by implementing preventive examination of health and conversation in general practitioner. DSI Rapport 2001.05
2002     Centre for Clinical Effectiveness (CCE) 'Open' versus 'closed' systems for enteral feeding
2000     Alberta Heritage Foundation for Medical Research (AHFMR) 'Soft copy' digital mammography
2024     NIHR Health Services and Delivery Research programme ‘Why are we stuck in hospital?’ Barriers to people with learning disabilities/autistic people leaving ‘long-stay’ hospital: a mixed methods study
2003     NIHR Health Technology Assessment programme "CLIP" Central Line Insertion Project, primary research
2005     Israel Center for Technology Assessment in Health Care (ICTAHC) "Publication profile" of an innovative technology - case study: coronary stent (abstract)
2005     Israel Center for Technology Assessment in Health Care (ICTAHC) "Techno-markers" for health technology utilization assessment (abstract)
2000     ECRI (111)In-capromab pendetide for staging prostate cancer in men at high risk of metastasis
2023     Center for Outcomes Research and Economic Evaluation for Health (C2H) (Cost-effectiveness evaluation of Valbenazine (Dysval) for tardive dyskinesia)
2021     Austrian Institute for Health Technology Assessment (AIHTA) (Good) practice organisational models using real-world evidence for public funding of high priced therapies
2018     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) (Percutaneous) left atrial appendage closure for the prevention of thromboembolic events in patients with atrial fibrillation. 3rd Update 2018
2018     NIHR Health Technology Assessment programme (REBALANCE) REview of Behaviour And Lifestyle interventions for severe obesity: AN evidenCE synthesis
2012     Basque Office for Health Technology Assessment (OSTEBA) [«BAatera Zainduz»: implementation of chronic disease management models in primary care, focused on the integration of assistance]
2008     Committee for New Health Technology Assessment (CNHTA) [1) PCCA gene, mutation[sequencing] 2) PCCB gene, mutation[sequencing]]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [10th Symposium Health Technology Assessment, Nothing without evidence? 18th-19th March 2010, Cologne]
2011     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [11th Symposium Health Technology Assessment, theoretical practice - practical theory? 17th to 18th March 2011, Cologne]
2010     Committee for New Health Technology Assessment (CNHTA) [18-f-sodium fluoride (18-f-naf) bone positron emission tomography, positron emission tomography/computed tomography]
2004     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [18-FDG positron emission tomography in oncology: HTA reports by international HTA agencies]
2021     Andalusian Health Technology Assessment Area (AETSA) [18F-FDG in myocardial viability for revascularization]
2010     Finnish Office for Health Care Technology Assessment (Finohta) [18Fluorodeoxyglucose positron emission tomography in the assessment of patients with potentially curable cancer]
2012     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [1st Expert Panel on viper venomous bite in Spain]
2023     Haute Autorite de sante (HAS) [2023 update: clinical utility of genomic signatures in early-stage HR-positive/HER2-negative breast cancer]
2007     Andalusian Health Technology Assessment Area (AETSA) [3 Tesla Magnetic Resonance Imaging]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [308nm excimer laser or 308nm excimer light in patients with vitiligo]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [3D Echocardiography in heart valve diseases]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [4CMenB vaccine for primary vaccination]
2010     Andalusian Health Technology Assessment Area (AETSA) [4D Ultrasound]
2007     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [8th Symposium Health Technology Assessment - Decision-making in medicine, 2007, October 18 - 19, Cologne]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [9th Symposium Health Technology Assessment - Patients in no man's land, 2008, October 17 - 18, Cologne]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [A classification algorithm for low back pain: matching patients to treatments that they are most likely to benefit from]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [A construction of support scheme for health technology evidence-generation in Korea]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [A controlled trial of geriatric liaison intervention in frail surgical oncology patients]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A health technology assessment of the effectiveness and safety of robot surgery]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [A health technology evaluation study for reviewing possibility of data linkage]
2025     Norwegian Medical Products Agency (NOMA) [A leadless pacemaker, MicraTM Transcatheter Pacing System, in (sub-groups of) patients with indication for single-chamber ventricular pacing: a single technology re-assessment]
2011     Haute Autorite de sante (HAS) [A priori evaluation of the expansion of newborn screening to one or more inborn error(s) of metabolism using the technology of tandem mass spectrometry in the general population in France. Part 1: medium chain CoA dehydrogenase deficiency (MCADD)]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [A prospective, randomised controlled trial comparing in-hospital treatment and early assisted discharge for exacerbations of chronic obstructive pulmonary disease (COPD)]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomised controlled trial comparing the cost-effectiveness of pelvic floor muscle exercise versus the TVT (O) procedure for female moderate to severe stress urinary incontinence]
2012     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomised controlled trial in the palliative setting regarding off-label medication: investigating the efficiency of amitriptyline versus pregabalin from a societal perspective]
2006     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomised cost-effectiveness study on the surgical versus conservative treatment of sciatica]
2011     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomized clinical trial of urinary incontinence in older women: cost-effectiveness of protocolized assessment and evidence-based treatment]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [A randomized controlled trial to assess the effectiveness of aspirin and anticoagulant treatment in women with unexplained recurrent miscarriage: ALIFE study (anticoagulants for living fetuses)]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A research on evidence-based healthcare for thyroid cancer screening: Part 1: the current status of thyroid cancer screening]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A research on evidence-based healthcare for thyroid cancer screening: Part 2: Effectiveness of ultrasonographic screening for thyroid cancer]
2013     Andalusian Health Technology Assessment Area (AETSA) [A review of indications for ventricular assist device therapy]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study of high-risk dyslipidemia for cardiocerebrovascular disease in Koreans]
2007     Center for Medical Technology Assessment (CMT) [A study of principles of compensation for health care services]
2010     National Evidence-based Healthcare Collaborating Agency (NECA) [A study of the effectiveness of self-care interventions for subclinical and mild depression]
2013     Basque Office for Health Technology Assessment (OSTEBA) [A study of the use of clinical practice guidelines in specialized care: barriers and facilitators to implementation]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on current issues of hearing aid use in Korean patients with hearing loss]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on current research status of psychiatric disorders, depression and suicide in Korea: Part Ⅰ. A study on current status and unmet need for the treatment of psychiatric disorders in Korea]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on current research status of psychiatric disorders, depression and suicide in Korea: Part Ⅱ. Study on adolescent depression and suicide]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on current research status of psychiatric disorders, depression and suicide in Korea: Part Ⅲ. A study on the current status and treatment promotion of comorbid depression among patients with cancer or patients with diabetes mellitus]
2010     Andalusian Health Technology Assessment Area (AETSA) [A study on efficacy, effectivity and efficiency of Intensity Modulated Radiotherapy (IMRT). Utility for treatment of breast and central nervous system neoplasms and sarcomas of bones and soft tissue]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on Korean adolescents' risk factors of suicide]
2016     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the effectiveness and needs of patient education in patients with rheumatoid arthritis]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the evaluation standards of osteoporosis in Korea]
2011     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the factors influencing adherence to antidepressant therapies and the cost-effectiveness of antidepressant therapies in Korea]
2014     National Evidence-based Healthcare Collaborating Agency (NECA) [A study on the system and execution model for health technology reassessment]
2021     Center for Drug Evaluation (CDE) [A systematic review of the comparative efficacy and cost-effectiveness of current listed statins in Taiwan]
2012     National Evidence-based Healthcare Collaborating Agency (NECA) [A systematic review of the diagnostic accuracy of FDG PET/PET-CT for fever of unknown origin]
2009     Committee for New Health Technology Assessment (CNHTA) [AB0-Rh(D) blood grouping automation test using CAT (column agglutination technology)]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abaloparatide (osteoporosis, postmenopausal women) – Benefit assessment according to §35a Social Code Book V]
2007     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Abatacept in the treatment of rheumatoid arthritis; systematic review and economic evaluation]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; adjuvant treatment) - Addendum to Commission A22-51]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Addendum to Commission A18-72]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; combination with an aromatase inhibitor) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; combination with fulvestrant) - Addendum to Commission A18-73]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer; combination with fulvestrant) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib in combination with an aromatase inhibitor (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abemaciclib in combination with fulvestrant (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Abemaciclib, palbociclib and ribociclib in breast cancer]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (New therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (prostate cancer) - Addendum to Commission A17-64]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abiraterone acetate (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2011     Finnish Office for Health Care Technology Assessment (Finohta) [Ablation therapy of liver tumors]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis, adolescents 12 years and older) – Benefit assessment according to § 35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis) - Addendum to Commission A22-06]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Abrocitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia; combination with obinutuzumab) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia; pretreated) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Addendum to Commission A20-105]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (pretreated chronic lymphocytic leukaemia) - Second Addendum to Commission A20-105]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with obinutuzumab) - Addendum to Commission A20-104]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia; combination with obinutuzumab) - Second Addendum to Commission A20-104]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia) - Addendum to Commission A20-103]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Acalabrutinib (previously untreated chronic lymphocytic leukaemia) - Second Addendum to Commission A20-103]
2008     Committee for New Health Technology Assessment (CNHTA) [Access flow measurement for hemodialysis]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Access routes of hysterectomy - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Accuracy and cost-effectiveness of diagnostic testing in patients with abdominal pain in general practice: a decision analysis]
2013     The Netherlands Organisation for Health Research and Development (ZonMw) [Accuracy and cost-effectiveness of two clinical decision rules for the diagnosis of deep vein thrombosis and pulmonary embolism in residents of nursing homes and homes for the elderly]
2025     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Accuracy of diagnostic algorithms for suspected or elevated risk of ovarian cancer]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Accuracy of FDG-PET and spiral CT for the early prediction of non-response to preoperative chemoradiotherapy in patients with esophageal cancer]